^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

zelavespib intravenous (PU-H71 IV)

i
Associations
Company:
Memorial Sloan-Kettering Cancer Center, Samus Therap
Drug class:
HSP90 inhibitor
Associations
Phase 1
Memorial Sloan Kettering Cancer Center
Completed
Last update posted :
03/28/2023
Initiation :
07/06/2011
Primary completion :
03/23/2023
Completion :
03/23/2023
JAK2 • CD4
|
JAK2 mutation
|
zelavespib intravenous (PU-H71 IV)
Phase 1b
Memorial Sloan Kettering Cancer Center
Completed
Last update posted :
12/20/2021
Initiation :
05/23/2017
Primary completion :
12/14/2021
Completion :
12/14/2021
HER-2 • ER
|
ER positive • HER-2 negative
|
albumin-bound paclitaxel • zelavespib intravenous (PU-H71 IV)